Michael Considine
Overview
Explore the profile of Michael Considine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
894
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Debeljak M, Cho S, Downs B, Considine M, Avin-McKelvey B, Wang Y, et al.
Breast Cancer Res
. 2024 Dec;
26(1):178.
PMID: 39633428
Background: Ductal carcinoma in-situ (DCIS) is a pre-invasive form of invasive breast cancer (IBC). Due to improved breast cancer screening, it now accounts for ~ 25% of all breast cancers....
2.
Godet I, Oza H, Shi Y, Joe N, Weinstein A, Johnson J, et al.
Nat Commun
. 2024 Sep;
15(1):8416.
PMID: 39341835
Hypoxia occurs in 90% of solid tumors and is associated with metastasis and mortality. Breast cancer cells that experience intratumoral hypoxia are 5x more likely to develop lung metastasis in...
3.
Chenoweth J, Colantuoni C, Striegel D, Genzor P, Brandsma J, Blair P, et al.
Nat Commun
. 2024 May;
15(1):4606.
PMID: 38816375
Our limited understanding of the pathophysiological mechanisms that operate during sepsis is an obstacle to rational treatment and clinical trial design. There is a critical lack of data from low-...
4.
Visvanathan K, Cope L, Fackler M, Considine M, Sokoll L, Carey L, et al.
Clin Cancer Res
. 2022 Dec;
29(4):784-790.
PMID: 36534524
Purpose: We previously demonstrated that high levels of circulating methylated DNA are associated with subsequent disease progression in women with metastatic breast cancer (MBC). In this study, we evaluated the...
5.
Harbison R, Pandey R, Considine M, Leone R, Murray-Stewart T, Erbe R, et al.
Cancer Res Commun
. 2022 Sep;
2(7):639-652.
PMID: 36052016
Metabolic features of the tumor microenvironment (TME) antagonize anti-tumor immunity. We hypothesized that T cell infiltrated tumors with a known antigen should exhibit superior clinical outcomes, though some fare worse...
6.
Sidiropoulos D, Rafie C, Jang J, Castanon S, Baugh A, Gonzalez E, et al.
Cancer Immunol Res
. 2022 Feb;
10(5):656-669.
PMID: 35201318
Therapeutic combinations to alter immunosuppressive, solid tumor microenvironments (TME), such as in breast cancer, are essential to improve responses to immune checkpoint inhibitors (ICI). Entinostat, an oral histone deacetylase inhibitor,...
7.
Thomas J, Zimmerlin L, Huo J, Considine M, Cope L, Zambidis E
NPJ Regen Med
. 2021 May;
6(1):25.
PMID: 34001907
Human pluripotent stem cells (hPSCs) can generate specialized cell lineages that have great potential for regenerative therapies and disease modeling. However, the developmental stage of the lineages generated from conventional...
8.
Humtsoe J, Kim H, Leonard B, Ling S, Keam B, Marchionni L, et al.
Cancer Res
. 2021 Jan;
81(4):1001-1013.
PMID: 33408119
Adenoid cystic carcinoma (ACC) is the second most common malignancy of the salivary gland. Although characterized as an indolent tumor, ACC often leads to incurable metastatic disease. Patients with ACC...
9.
Pisanic 2nd T, Wang Y, Sun H, Considine M, Li L, Wang T, et al.
Clin Cancer Res
. 2020 Aug;
26(23):6310-6320.
PMID: 32817081
Purpose: The current paradigm in the development of high-grade serous ovarian carcinoma (HGSC) proposes that the majority of HGSCs arise from precursor serous tubal intraepithelial carcinoma (STIC) lesions of the...
10.
Kagohara L, Zamuner F, Davis-Marcisak E, Sharma G, Considine M, Allen J, et al.
Br J Cancer
. 2020 Jul;
123(10):1582-1583.
PMID: 32694696
An amendment to this paper has been published and can be accessed via a link at the top of the paper.